Christopher B Granger

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Apixaban versus warfarin in patients with atrial fibrillation
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:981-92. 2011
  2. doi request reprint Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease
    Svati H Shah
    Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 163:844-850.e1. 2012
  3. ncbi request reprint Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry)
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 104:1285-91. 2009
  4. doi request reprint Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 163:797-803. 2012
  5. pmc Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Crit Care Med 39:78-83. 2011
  6. doi request reprint Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis
    Tracy Y Wang
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am J Med 125:1214-21. 2012
  7. pmc Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients
    Connie N Hess
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 164:607-15. 2012
  8. doi request reprint Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 109:320-6. 2012
  9. doi request reprint Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 159:331-9. 2010
  10. ncbi request reprint Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin
    E Marc Jolicoeur
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 104:292-7. 2009

Collaborators

Detail Information

Publications143 found, 100 shown here

  1. doi request reprint Apixaban versus warfarin in patients with atrial fibrillation
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:981-92. 2011
    ..Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin...
  2. doi request reprint Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease
    Svati H Shah
    Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 163:844-850.e1. 2012
    ..Cardiovascular risk models remain incomplete. Small-molecule metabolites may reflect underlying disease and, as such, serve as novel biomarkers of cardiovascular risk...
  3. ncbi request reprint Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry)
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 104:1285-91. 2009
    ..98, p = 0.03). In conclusion, the 6-month mortality rate among heparin-treated patients with thrombocytopenia is high, although the risk independently related to thrombocytopenia appears to be restricted to the acute hospital phase...
  4. doi request reprint Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 163:797-803. 2012
    ..Information on practice patterns and outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary interventions (PCIs) in Canada vs United States is limited...
  5. pmc Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Crit Care Med 39:78-83. 2011
    ..The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment...
  6. doi request reprint Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis
    Tracy Y Wang
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am J Med 125:1214-21. 2012
    ..Heparin is commonly used for venous thromboembolism prophylaxis; however, the incidence of acquired thrombocytopenia in this setting has not been well described...
  7. pmc Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients
    Connie N Hess
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 164:607-15. 2012
    ..Balancing safe and effective use of aspirin, clopidogrel, and warfarin in this population is important...
  8. doi request reprint Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 109:320-6. 2012
    ..These data highlight the importance of understanding factors associated with gender-related differences in bleeding and represent an opportunity for improving outcomes of women and men with fibrinolytic-treated STEMI...
  9. doi request reprint Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 159:331-9. 2010
    ....
  10. ncbi request reprint Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin
    E Marc Jolicoeur
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 104:292-7. 2009
    ..77, 95% confidence interval 1.67 to 4.61, respectively). In conclusion, medical management should be directed mainly at the prevention of thromboembolic complications, while additionally considering the risk for bleeding...
  11. ncbi request reprint Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Med 125:897-905. 2012
    ..Atrial fibrillation guidelines recommend long-term use of warfarin according to a patient's predicted risk of stroke. After acute myocardial infarction, however, combining warfarin and antiplatelet medications poses challenges...
  12. pmc Metabolic profiles predict adverse events after coronary artery bypass grafting
    Asad A Shah
    Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Thorac Cardiovasc Surg 143:873-8. 2012
    ..Novel molecular technologies can identify biomarkers to improve risk stratification. We examined whether metabolic profiles can predict adverse events in patients undergoing coronary artery bypass grafting...
  13. doi request reprint Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial
    Sana M Al-Khatib
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Eur Heart J 34:2464-71. 2013
    ..It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF)...
  14. pmc Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311, Terrace Level, Box 3850, Durham, NC 27705, USA
    Trials 14:123. 2013
    ..We evaluated alternative approaches to quantifying infarct size using CK-MB values, and the relationship between infarct size and clinical outcomes...
  15. doi request reprint The impact of a statewide pre-hospital STEMI strategy to bypass hospitals without percutaneous coronary intervention capability on treatment times
    Emil L Fosbol
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 7461, Terrace Level, Durham, NC 27705, USA
    Circulation 127:604-12. 2013
    ..North Carolina has adopted a statewide STEMI referral strategy that advises paramedics to bypass local hospitals and transport STEMI patients directly to a PCI-capable hospital, even if a non-PCI-capable hospital is closer...
  16. pmc Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights
    Sean van Diepen
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Circ Cardiovasc Qual Outcomes 5:437-44. 2012
    ..We examined the association between door 1-to-door 2 (D1D2) time, a measure capturing the entire transfer process, and outcomes in patients undergoing interhospital transfer for primary percutaneous coronary intervention...
  17. doi request reprint Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Med 123:134-40. 2010
    ....
  18. ncbi request reprint Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies
    Richard E Waters
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 146:958-68. 2003
    ..Thus, as the reperfusion era continues to evolve, the ideal treatment strategy for patients with STEMI is being redefined to integrate pharmacologic and mechanical approaches to reperfusion...
  19. doi request reprint Bypassing the emergency department and time to reperfusion in patients with prehospital ST-segment-elevation: findings from the reperfusion in acute myocardial infarction in Carolina Emergency Departments project
    Akshay Bagai
    Department of Cardiology, Duke Clinical Research Institute, Duke University, Durham, NC 27705, USA
    Circ Cardiovasc Interv 6:399-406. 2013
    ....
  20. ncbi request reprint Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program
    Akshay Bagai
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Circulation 128:352-9. 2013
    ..For patients identified before hospital arrival with ST-segment-elevation myocardial infarction, bypassing the emergency department (ED) with direct transport to the catheterization laboratory may shorten reperfusion times...
  21. ncbi request reprint Acute kidney injury and cardiovascular outcomes in acute severe hypertension
    Lynda A Szczech
    Department of Medicine, Division of Nephrology, Duke University Medical Center, Box 3646, Durham, NC 27710, USA
    Circulation 121:2183-91. 2010
    ....
  22. doi request reprint Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am J Med 124:48-57. 2011
    ....
  23. ncbi request reprint Economic assessment of thrombocytopenia: CATCH Registry
    Eric L Eisenstein
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    J Med Syst 34:379-86. 2010
    ..001); and (group 3) (difference, $27,077; 95% CI, $22,901-$31,252; P<.001). However, in our adjusted model, longer lengths-of-stay and greater use of blood transfusions accounted for most incremental in-hospital cost differences...
  24. ncbi request reprint Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction
    Padma Kaul
    Department of Medicine, Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 149:637-44. 2005
    ....
  25. doi request reprint Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study
    Akshay Bagai
    Duke Clinical Research Institute, Durham, NC Electronic address
    Am Heart J 166:913-9. 2013
    ..We sought to determine the prognostic value of LVEDP measured during primary PCI for ST-segment elevation myocardial infarction (STEMI)...
  26. doi request reprint Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes
    Jeffrey T Guptill
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Circ Cardiovasc Interv 6:176-83. 2013
    ..Little is known about stroke timing, characteristics, and clinical outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (PCI)...
  27. pmc Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes
    Adriano A M Truffa
    Duke Clinical Research Institute and the Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27705, USA
    JACC Cardiovasc Interv 5:769-76. 2012
    ..We also assessed the association between serious infections and 90-day death or death/myocardial infarction (MI)...
  28. doi request reprint Expansion of a regional ST-segment-elevation myocardial infarction system to an entire state
    James G Jollis
    Duke Clinical Research Institute, Duke University, Durham, NC 27710, USA
    Circulation 126:189-95. 2012
    ..Despite national guidelines calling for timely coronary artery reperfusion, treatment is often delayed, particularly for patients requiring interhospital transfer...
  29. doi request reprint Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction
    James S Mills
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Coron Artery Dis 23:118-25. 2012
    ....
  30. doi request reprint International variation in and factors associated with hospital readmission after myocardial infarction
    Robb D Kociol
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    JAMA 307:66-74. 2012
    ..Recently, 30-day readmission rates have been proposed as a metric for care of patients with STEMI. However, international rates and predictors of 30-day readmission after STEMI have not been studied...
  31. doi request reprint Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues
    E Marc Jolicoeur
    Duke University, Durham, NC, USA
    Am Heart J 155:435-44. 2008
    ..The present part reviews the current status of understanding of advanced CAD, the limits of contemporary therapies, and the difficulties in and barriers to the development of new treatments...
  32. doi request reprint Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease
    Svati H Shah
    Duke University Medical Center, Durham, NC, USA
    Am Heart J 160:371-379.e2. 2010
    ..Clinical predictive models leave gaps in our ability to stratify cardiovascular risk. High-throughput molecular profiling promises to improve risk classification...
  33. pmc Regional systems of care demonstration project: Mission: Lifeline STEMI Systems Accelerator: design and methodology
    Akshay Bagai
    Duke Clinical Research Institute, Durham, NC
    Am Heart J 167:15-21.e3. 2014
    ..The impact of regionalization of STEMI care on clinical outcomes will be evaluated. ..
  34. doi request reprint Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC Electronic address
    Am Heart J 166:559-65. 2013
    ..3% of subjects in the apixaban group and 1.2% of subjects in the warfarin group received, at some point during the study, a container of the wrong type."..
  35. doi request reprint Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Lancet 380:1749-58. 2012
    ..We assessed in this trial's participants how results differed according to patients' CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, used to predict the risk of stroke and bleeding...
  36. doi request reprint Promise of factor Xa inhibition in atrial fibrillation
    Sana M Al-Khatib
    Division of Cardiology, Department of Medicine, Duke Clinical Research Institute and Duke University, 2400 Pratt Street, PO Box 17969, Durham, NC 27705, USA
    Curr Cardiol Rep 14:70-8. 2012
    ....
  37. doi request reprint Care processes associated with quicker door-in-door-out times for patients with ST-elevation-myocardial infarction requiring transfer: results from a statewide regionalization program
    Seth W Glickman
    Duke Clinical Research Institute and Department of Medicine, Duke University School of Medicine, 170 Manning Drive, Durham, NC 27599, USA
    Circ Cardiovasc Qual Outcomes 4:382-8. 2011
    ..Our objective was to assess the association of prehospital, emergency department (ED), and hospital processes of care implemented as part of a statewide STEMI regionalization program with door-in-door-out times at non-PCI hospitals...
  38. doi request reprint Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, P O Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 36:115-30. 2013
    ..This paper summarizes the symposium proceedings...
  39. doi request reprint Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
    Manesh R Patel
    Duke Cardiovascular Magnetic Resonance Center, Durham, NC, USA
    Am Heart J 165:226-33. 2013
    ..We examined the association among AbMI, other metrics of infarct size, and left ventricular (LV) function defined by cardiac magnetic resonance (CMR)...
  40. doi request reprint Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial
    Sean van Diepen
    Duke Clinical Research Institute, Duke University Medical Center, North Pavilion, 2400 Pratt Street, Durham, NC 27705, USA
    J Thromb Thrombolysis 34:106-13. 2012
    ..This finding is consistent with pre-clinical and clinical research suggesting that systemic inflammation may influence NT-proBNP expression independently of myocardial stretch...
  41. doi request reprint Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Box 17969, Durham, NC 27715, USA
    Eur Heart J 29:880-7. 2008
    ....
  42. doi request reprint Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 57:138-46. 2011
    ..The purpose of this study was to examine the association between lower socioeconomic status (SES), as ascertained by years of education, and outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI)...
  43. ncbi request reprint International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 101:25-29. 2008
    ....
  44. doi request reprint The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction
    Sean van Diepen
    Division of Cardiology and Critical Care, University of Alberta, Edmonton, Alberta, Canada
    Crit Care Med 41:2080-7. 2013
    ..To assess whether systemic inflammatory response syndrome is associated with morbidity and mortality in ST-elevation myocardial infarction...
  45. pmc Hospital length of stay in patients with non-ST-segment elevation myocardial infarction
    John P Vavalle
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am J Med 125:1085-94. 2012
    ..Substantial heterogeneity in hospital length of stay exists among patients admitted with non-ST-segment elevation myocardial infarction. Furthermore, little is known about the factors that impact length of stay...
  46. doi request reprint Prehospital system delay in ST-segment elevation myocardial infarction care: a novel linkage of emergency medicine services and in hospital registry data
    Emil L Fosbøl
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 165:363-70. 2013
    ..Emergency medical services (EMS) are critical in the treatment of ST-segment elevation myocardial infarction (STEMI). Prehospital system delays are an important target for improving timely STEMI care, yet few limited data are available...
  47. pmc Transport time and care processes for patients transferred with ST-segment-elevation myocardial infarction: the reperfusion in acute myocardial infarction in Carolina emergency rooms experience
    Daniel Munoz
    Duke Clinical Research Institute, Duke University, Durham, NC 27705, USA
    Circ Cardiovasc Interv 5:555-62. 2012
    ..We examine the association between transfer drive times and door-to-device (D2D) times in a network of North Carolina hospitals. We compare the feasibility of timely percutaneous coronary intervention using ground versus air transfer...
  48. doi request reprint Effect of heparin administration on metabolomic profiles in samples obtained during cardiac catheterization
    Michael P Brunner
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Circ Cardiovasc Genet 4:695-700. 2011
    ..Because it stimulates lipolysis, heparin is a potential confounder of metabolic profiling in these populations...
  49. doi request reprint Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 155:369-74. 2008
    ..We sought to determine the relationship between bleeding, blood transfusion, and measures of costs among patients with non-ST-segment elevation ACS...
  50. doi request reprint Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study)
    Manesh R Patel
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 103:181-6. 2009
    ..In conclusion, in this observational analysis of stent use from a large primary percutaneous intervention for acute MI trial, DESs appear as safe as BMSs with similar 6-month clinical outcomes with regard to death and recurrent MI...
  51. pmc Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707, USA
    Eur Heart J 30:2019-28. 2009
    ..To assess the incidence and timing of atrial fibrillation (AF), describe antithrombotic therapy use, and evaluate the association of AF with 90 day mortality and other secondary clinical outcomes...
  52. doi request reprint Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention
    E Marc Jolicoeur
    Duke Clinical Research Institute, Box 3409, Durham, NC 27710, USA
    Eur Heart J 30:2575-83. 2009
    ..We describe the association between transfusion and 90-day mortality among patients with acute myocardial infarction treated with primary percutaneous coronary intervention...
  53. doi request reprint Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 161:782-9. 2011
    ....
  54. doi request reprint Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 32:242-66. 2011
    ..This paper summarizes the symposium proceedings...
  55. doi request reprint Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy
    Sean van Diepen
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada Electronic address
    Int J Cardiol 168:2127-33. 2013
    ..Whether STEMI clinical prediction models can be improved with the addition of baseline inflammatory biomarkers remains unknown...
  56. doi request reprint Systems of care for ST-segment-elevation myocardial infarction: a report From the American Heart Association's Mission: Lifeline
    James G Jollis
    Duke University Medical Center, Durham, NC, USA
    Circ Cardiovasc Qual Outcomes 5:423-8. 2012
    ..In order to characterize currently implemented STEMI reperfusion systems and identify practices common to system organization, the American Heart Association surveyed existing systems throughout the United States...
  57. doi request reprint Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 34:143-63. 2012
    ..This paper summarizes the symposium proceedings...
  58. doi request reprint Assessment of temporal trends in mortality with implementation of a statewide ST-segment elevation myocardial infarction (STEMI) regionalization program
    Seth W Glickman
    Duke Clinical Research Institute, Duke University, Durham, NC, USA
    Ann Emerg Med 59:243-252.e1. 2012
    ..Our objective is to explore temporal trends in STEMI mortality with the implementation of a statewide STEMI regionalization program (Reperfusion of Acute Myocardial Infarction in North Carolina Emergency Departments [RACE])...
  59. doi request reprint Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction
    David M Lofthus
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Coron Artery Dis 23:22-30. 2012
    ..The incidence of liver enzyme elevations in STEMI, temporal trends, correlations with creatine kinase-MB (CK-MB), and associations with clinical outcomes were evaluated...
  60. doi request reprint Diagnosing acute myocardial infarction in patients with left bundle branch block
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 108:782-8. 2011
    ....
  61. doi request reprint Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005
    Kevin Jackson
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 155:829-40. 2008
    ..With this summary document, we hope to provide a helpful resource for future drug development for AF...
  62. doi request reprint A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial
    Amanda Stebbins
    Duke Clinical Research Institute, Durham, NC, USA
    Circ Cardiovasc Interv 3:414-22. 2010
    ..Accurate models to predict mortality are needed for risk stratification in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)...
  63. ncbi request reprint Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction
    Manesh R Patel
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 151:316-22. 2006
    ..Cardiac tamponade is a life-threatening complication of acute myocardial infarction (MI). Data on the incidence, risk factors, and outcome of tamponade in patients with acute MI in the fibrinolytic era are limited...
  64. pmc Peakwide mapping on chromosome 3q13 identifies the kalirin gene as a novel candidate gene for coronary artery disease
    Liyong Wang
    Center for Human Genetics, Department of Medicine, Duke Univeristy Medical Center, Durham, NC, USA
    Am J Hum Genet 80:650-63. 2007
    ..KALRN and two other associated genes identified in this study (CDGAP and MYLK) belong to the Rho GTPase-signaling pathway. Our data suggest the importance of the KALRN gene and the Rho GTPase-signaling pathway in the pathogenesis of CAD...
  65. ncbi request reprint Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial)
    Manesh R Patel
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 95:614-8. 2005
    ..Baseline and serial measurements of WBC counts and temperature were correlated with infarct size and clinical outcome...
  66. ncbi request reprint Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy
    Jeffrey S Berger
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 117:192-9. 2008
    ..We therefore compared the acute mortality and bleeding risks associated with the initial use of 162 versus 325 mg aspirin in fibrinolytic-treated ST-elevation myocardial infarction patients...
  67. doi request reprint Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention
    Rajendra H Mehta
    Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
    JAMA 301:1779-89. 2009
    ....
  68. ncbi request reprint Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial)
    David E Kandzari
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 93:458-61. 2004
    ..4, 95% confidence interval 1.2 to 10.2). Because facial or head trauma may greatly influence treatment decisions, this risk factor should be incorporated into models designed to estimate the risks and benefits of fibrinolytic therapy...
  69. pmc GATA2 is associated with familial early-onset coronary artery disease
    Jessica J Connelly
    Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
    PLoS Genet 2:e139. 2006
    ....
  70. ncbi request reprint The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2
    Michael C Tjandrawidjaja
    Department of Medicine, Division of Cardiology, 2 51 Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
    Eur Heart J 24:1024-34. 2003
    ..To assess gender differences in patients with early reinfarction after fibrinolysis for acute myocardial infarction (AMI) and the impact of these differences on treatment and outcomes...
  71. doi request reprint Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial
    Manesh R Patel
    Duke University, Durham, North Carolina 27710, USA
    JACC Cardiovasc Imaging 3:52-60. 2010
    ..The purpose of the study was to understand determinants of infarct size in a primary percutaneous intervention (PCI) population treated with pexelizumab compared with placebo...
  72. doi request reprint Adherence to medication according to sex and age in the CHARM programme
    Bradi B Granger
    Duke University Health System, Duke University School of Nursing, Durham, NC 27710, USA
    Eur J Heart Fail 11:1092-8. 2009
    ..Although many patients with heart failure have incomplete adherence to prescribed medications, predisposing factors remain unclear. This analysis investigates factors associated with adherence, with particular emphasis on age and sex...
  73. pmc ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention
    Svati H Shah
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States
    Atherosclerosis 201:148-54. 2008
    ..There is no accurate way to predict in-stent restenosis, although risk factors for atherosclerosis overlap those for in-stent restenosis. Therefore, we evaluated atherosclerosis candidate genes for association with in-stent restenosis...
  74. ncbi request reprint Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Interv Cardiol 20:299-306. 2007
    ..Adverse events occur following non-ST elevation acute coronary syndromes (NSTE ACS). However, the timing of these events in relation to index event is less clear...
  75. ncbi request reprint Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention
    Peter R Sinnaeve
    Duke Clinical Research Center, Durham, NC, USA
    Eur Heart J 26:2396-403. 2005
    ..heparin...
  76. ncbi request reprint Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials
    John M Galla
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:16-24. 2006
    ..A concomitant goal was to contribute insight to the debate over how patients with NSTE ACS should be managed...
  77. ncbi request reprint Reducing cardiac events after acute coronary syndromes
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Rev Cardiovasc Med 5:S39-46. 2004
    ....
  78. ncbi request reprint Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27710, USA
    JAMA 293:1746-50. 2005
    ..Incorrect dosing of alteplase has been associated with worse clinical outcomes in patients. However, patients at high risk of adverse events are more prone to dosing errors, thus confounding this relationship...
  79. ncbi request reprint Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 45:471-8. 2005
    ..Clearly targeted large-scale clinical trials are needed to evaluate the relative merits of available reperfusion strategies as well as newer antithrombotic adjunctive therapies in the elderly with STEMI...
  80. ncbi request reprint Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary int
    Paul W Armstrong
    Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Am Heart J 149:402-7. 2005
  81. pmc Fine mapping of a linkage peak with integration of lipid traits identifies novel coronary artery disease genes on chromosome 5
    Daniel K Nolan
    Center for Human Genetics, Duke University, 905 S, LaSalle Street, Duke Univeristy Medical Center, Durham, NC 27710, USA
    BMC Genet 13:12. 2012
    ..e., a qualitative phenotype) using linkage and association in the presence of linkage (APL; GENECARD) and logistic regression (CATHGEN and aortas)...
  82. doi request reprint The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale
    Chiara Melloni
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 164:646-653.e3. 2012
    ..Information gained from the SOLSTICE trial will inform further testing of this agent in larger clinical trials...
  83. ncbi request reprint Reasons for noncompletion of advance directives in a cardiac intensive care unit
    Rebecca W Johnson
    Department of Nursing, Duke University Health System, Durham, North Carolina, USA
    Am J Crit Care 21:311-20. 2012
    ..The Patient Self-Determination Act of 1990 mandates that hospitals reimbursed by Medicare and Medicaid inform each patient about the patient's right to a natural death...
  84. doi request reprint Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies
    E Marc Jolicoeur
    Duke University, Durham, NC, USA
    Am Heart J 155:418-34. 2008
    ..Trial design, end points, and regulatory issues will be discussed in the second part of the article...
  85. doi request reprint Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Contemp Clin Trials 32:178-87. 2011
    ..Independent adjudication of clinical trial events is traditionally performed by physicians on a clinical event classification (CEC) committee...
  86. doi request reprint Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Contemp Clin Trials 29:887-95. 2008
    ..The operational paradigm of this effort should be considered in future investigations so that important advances in clinical care of disease can be realized efficiently...
  87. doi request reprint Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registry
    Jason N Katz
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 158:599-606.e1. 2009
    ..Limited data are available on the care of patients with acute severe hypertension requiring hospitalization. We characterized contemporary practice patterns and outcomes for this population...
  88. doi request reprint Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Thromb Thrombolysis 26:167-74. 2008
    ....
  89. doi request reprint Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy
    Gustavo B F Oliveira
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt St, Durham, NC 27705, USA
    Arch Intern Med 168:94-102. 2008
    ..Despite widespread heparin use in clinical practice, the associated development of thrombocytopenia is an underrecognized and undertreated complication...
  90. doi request reprint Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
    Kent R Nilsson
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Heart 96:838-42. 2010
    ..This study compared a rate control strategy to an anti-arrhythmic-based rhythm control strategy for the treatment of AF following myocardial infarction...
  91. pmc Medication adherence: a call for action
    Hayden B Bosworth
    Center for Health Services Research in Primary Care, Durham VAMC, Durham, NC, USA
    Am Heart J 162:412-24. 2011
    ..We then summarize proven effective approaches and conclude with a discussion of recommendations to address this growing and significant public health issue of medication nonadherence...
  92. doi request reprint Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rap
    Jeffrey S Berger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 158:998-1004.e1. 2009
    ..We examined the safety and tolerability of a novel, direct-acting, reversible, intravenous P2Y12 ADP-receptor antagonist, elinogrel, versus placebo when administered to STEMI patients before primary PCI...
  93. ncbi request reprint The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events
    L Kristin Newby
    Duke Clinical Research Institute, Durham, North Carolina 27707, USA
    Am J Med 112:647-58. 2002
    ..To understand these findings, we performed a meta-analysis of results from four phase 3 trials...
  94. ncbi request reprint Thresholds for the electrocardiographic change range of biochemical markers of acute myocardial infarction (GUSTO-IIa data)
    Maria Cecilia Bahit
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 90:233-7. 2002
    ..8 (upper limit of normal 1.5 ng/ml). This study revealed that 95% of the patients with definite ECG evidence of AMI had a more than twofold increase in CK-MB and more than a 3- to 11-fold increase in troponin...
  95. ncbi request reprint Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries
    Ian C Gilchrist
    Division of Cardiology, Department of Medicine, Pennsylvania State University, Hershey, PA, USA
    Am Heart J 144:73-80. 2002
    ..This study analyzed relationships among heparin dosage, patient characteristics, and 30-day outcome because optimal unfractionated-heparin dosing in acute coronary syndromes remains uncertain...
  96. ncbi request reprint Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI
    Michael C Tjandrawidjaja
    Division of Cardiology, Department of Medicine, University of Alberta, 2 51 Medical Sciences Building, Edmonton, Alberta T6G 2H7, Canada
    Eur Heart J 28:2850-7. 2007
    ..To examine the extent and impact on clinical outcomes of adherence to electrocardiogram (ECG) entry criteria in ST-elevation myocardial infarction patients in the assessment of pexelizumab in acute myocardial infarction (APEX-AMI) trial...
  97. doi request reprint Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial
    S Michael Gharacholou
    Division of Cardiology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Arch Intern Med 171:559-67. 2011
    ....
  98. doi request reprint Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil
    Renato D Lopes
    Duke University School of Medicine, Durham, NC, USA
    J Thromb Thrombolysis 28:106-16. 2009
    ..This article is a focused summary of the symposium proceedings...
  99. doi request reprint Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events
    Karen S Pieper
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 157:1097-105. 2009
    ..The aim of this study was to explore the impact of modeling techniques on the risk model when generating predictions...
  100. ncbi request reprint Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone
    J Conor O'Shea
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 90:1374-7. 2002
  101. ncbi request reprint Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 152:291-6. 2006
    ....